Disclosures: Oluwaseun Falade-Nwulia: AbbVie Inc: Grant/Research Support, Gilead Sciences: Advisor, Jennifer Price: Nothing to Disclose, Jordan Feld: Mirum: Consultant, AbbVie, Bluejays, Gilead, Janssen, GSK, Roche, VIR Roche: Consultant, Bluejays: Consultant, Gilead: Consultant, Janssen: Consultant, GSK: Consultant, Roche: Consultant, VIR Biotechnology: Consultant, Altimmune, AbbVie, Gilead, Jannsen, GSK, Roche, VIR Bio: Grant/Research Support, Ellen Eaton: Gilead Foundation: Patient Engagement Working Group, Franco Ricardo: Nothing to Disclose, Brittany Barnaba: Pfizer, Inc.: Stock - publicly traded company, Diane Brown: Nothing to Disclose, Sarah Hussain: Nothing to Disclose, Catherine Wren: Nothing to Disclose, Hamidreza Karimi Sari: Nothing to Disclose, Kyoko Hirose: Nothing to Disclose, Chris Cavacuiti: Nothing to Disclose, Stephen O'rear: Nothing to Disclose, Camelia Capraru: Nothing to Disclose, Karin Tobin: Nothing to Disclose, Sheree Schwartz: Nothing to Disclose, Mark Sulkowski: Nothing to Disclose 705 REGNASE-1 DOWN-REGULATION CONTRIBUTES TO MYELOID CELL INTERMEDIATED ICC DEVELOPMENT Yu Sato 1 Takahiro Kodama 1 Yoshinobu Saito 1 Yuki Tahata 1 Kazuhiro Murai 1 Akira Doi 1 Kumiko Shirai 1 Kazuki Maesaka 1 Hayato Hikita 1 Tomohide Tatsumi 1 Tetsuo Takehara 1 , 1 Osaka University Background: The tumor immune microenvironment (TIME) is a therapeutic target for primary liver cancers
Expertise in Acne Scar Treatment Our Los Angeles providers have extensive experience treating acne scars with Morpheus8 across all skin types and scar patterns
then apply a cream, and in the morning be sure to apply broad-spectrum SPF protection
Mol Biosyst
